Alzheimer's disease: The cholesterol connection

Nature Neuroscience

Volumn 6, Issue 4, 2003, Pages 345-351

  Puglielli, Luigi ^a   Tanzi, Rudolph E ^a   Kovacs, Dora M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL;

ALZHEIMER DISEASE; BIOGENESIS; BRAIN REGION; CHOLESTEROL SYNTHESIS; DISEASE ASSOCIATION; GENETIC RISK; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; CHOLINERGIC ANTAGONISTS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURONS;

EID: 0345669752     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn0403-345     Document Type: Review

References (70)

1. Tanzi, R.E. & Bertram, L. New frontiers in Alzheimer's disease genetics. Neuron 32, 181-184 (2001).
2. Thinakaran, G. The role of presenilins in Alzheimer's disease. J. Clin. Invest. 104, 1321-1327 (1999).
3. Blacker, D. et al. Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Hum. Mol. Genet. 12, 23-32 (2003).
4. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, 23-31 (1999).
5. Price, D.L., Tanzi, R.E., Borchelt, D.R., & Sisodia, S.S. Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461-493 (1998).
6. Cao, X. & Sudhof, T.C. A transcriptionally active complex of APP with FE65 and histone acethyltransferase Tip60. Science 293, 115-120 (2001).
7. Kimberly, W.T., Zheng, J.B., Guenette, S.Y. & Selkoe, D.J. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner. J. Biol. Chem. 276, 40288-40292 (2001).
8. Bales, K.R. et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263-264 (1997).
9. Bales, K.R. et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 96, 15233-15238 (1999).
10. Holtzman, D.M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 2892-2897 (2000).
11. LaDu, M.J. et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23403-23406 (1994).
12. Naslund, J. et al. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 15, 219-228 (1995).
13. Yang, D.S. et al. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90, 1217-1226 (1999).
14. Van Uden, E. et al. A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity. J. Biol. Chem. 275, 30525-30530 (2000).
15. Chung, H., Brazil, M.I., Soe, T.T. & Maxfield, F.R. Uptake, degradation and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J. Biol. Chem. 274, 32301-32308 (1999).
16. Ulery, P.G. et al. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). J. Biol. Chem. 275, 7410-7415 (2000).
17. Herz, J. & Beffert, U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci. 1, 51-58 (2000).
18. Strittmatter, W.J. et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098-8102 (1993).
19. Ma, J., Yee, A., Brewer, H.B. Jr., Das, S. & Potter, H. Amyloid-associated proteins alpha1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92-94 (1994).
20. Sanan, D.A. et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94, 860-869 (1994).
21. Holtzman, D.M. Role of apoE/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J. Mol. Neurosci. 17, 147-155 (2001).
22. Fagan, A.M. et al. Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305-318 (2002).
23. Ehnholm, C., Lukka, M., Kuusi, T., Nikkila, E. & Utermann, G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J. Lipid Res. 27, 227-235 (1986).
24. Boerwinkle, E. et al. The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am. J. Med. Genet. 27, 567-582 (1987).
25. Papassotiropoulos, A. et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27-32 (2002).
26. Jarvik, G.P. et al. Interaction of apolipoprotein E genotype, total cholesterol level, and sex in prediction of Alzheimer disease in a case-control study. Neurology 45, 1092-1096 (1995).
27. Kuo, Y.M. et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain βP 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711-715 (1998).
28. Fernandes, M.A. et al. Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer's disease. Biochim. Biophys. Acta. 1454, 89-96 (1999).
29. Knebl, J. et al. Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech. Ageing Dev. 73, 69-77 (1994).
30. Hofman, A. et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 349, 151-154 (1997).
31. Mori, T. et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60, 778-785 (2001).
32. Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S. & Drachman, D.A. Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
33. Wolozin, B. & Behl, C. Mechanisms of neurodegenerative disorders: protein aggregates. Arch. Neurol. 57, 793-796 (2000).
34. Yaffe, K., Barrett-Connor, E., Lin, F. & Grady, D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59, 378-384 (2002).
35. Rockwood, K. et al. Use of lipid-lowering agents, indication bias and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227 (2002).
36. Simons, M. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346-350 (2002).
37. Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002).
38. Petanceska, S., Papolla, M. & Refolo, L. Modulation of Alzheimer's amyloidosis by statins: mechanism of action. Curr. Med. Chem. Imun. Endocrinol. Metab. Agents 3, 233-243 (2003).
39. Corsini, A. Fluvastatin: effects beyond cholesterol lowering. J. Cardiovasc. Pharmacol. Ther. 5, 161-175 (2000).
40. Sparks, D.L. et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94 (1994).
41. Sparks, D.L., Kuo, Y.M., Roher, A., Martin, T. & Lukas, R.J. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann. NY Acad. Sci. 903, 335-344 (2000).
42. Refolo, L.M. et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331 (2000).
43. Refolo, L.M. et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899 (2001).
44. Howland, D.S. et al. Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J. Biol. Chem. 273, 16576-16582 (1998).
45. Fassbender, K. et al. Simvastatin strongly reduces levels of Alzheimer's disease beta- amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856-5861 (2001).
46. Refolo, L.M., Wittenberg, I.S., Friedrich V.L. Jr. & Robakis, N.K. The Alzheimer amyloid precursor is associated with the detergent-insoluble cytoskeleton. J. Neurosci. 11, 3888-3897 (1991).
47. Lee, S.J. et al. A detergent-insoluble membrane compartment contains Aβ in vivo. Nat. Med. 4, 730-734 (1998).
48. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113-123 (2003).
49. Choo-Smith, L.P. & Surewicz, W.K. The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95-98 (1997).
50. Yanagisawa, K., McLaurin, J., Michikawa, M., Chakrabartty, A. & Ihara, Y. Amyloid beta-protein (Aβ) associated with lipid molecules: immunoreactivity distinct from that of soluble Aβ. FEBS Lett. 420, 43-46 (1997).
51. Yanagisawa, K., Odaka, A., Suzuki, N. & Ihara, Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062-1066 (1995).
52. Simons, M. et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460-6464 (1998).
53. Frears, E.R., Stephens, D.J., Walters, C.E., Davies, H. & Austen, B.M. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10, 1699-1705 (1999).
54. Bodovitz, S. & Klein, W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436-4440 (1996).
55. Racchi, M. et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 322, 893-898 (1997).
56. Kojro, E., Gimpl, G., Lammich, S., Marz, W. & Fahrenholz, E Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98, 5815-5820 (2001).
57. Runz, H. et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22, 1679-1689 (2002).
58. Fukumoto, H., Deng, A., Irizarry, M.C., Fitzgerald, M.L. & Rebeck, G.W. Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor aginists increases secreted Aβ levels. J. Biol. Chem. 277, 48508-48513 (2002).
59. Puglielli, L. et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905-912 (2001).
60. Chang, T.Y. et al. Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. 12, 289-296 (2001).
61. Chang, T.Y., Chang, C.C., Lu, X. & Lin, S. Catalysis of ACAT may be completed within the plane of the membrane. A working hypothesis. J. Lipid Res. 42, 1933-1938 (2001).
62. Brown, M.S. & Goldstein, J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc. Natl. Acad. Sci. USA 96, 11041-11048 (1999).
63. Tschape, J.A. et al. The neurodegeneration mutant lochrig interferes with cholesterol homeostasis and Appl processing. EMBO J. 21, 6367-6376 (2002).
64. Dietschy, J.M. & Turley, S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105-112 (2001).
65. Snipes, G.J. & Suter, U. Cholesterol and myelin in Subcellular Biochemistry. Cholesterol: its Functions and Metabolism in Biology and Medicine (ed. Bittman, R.) 173-204 (Plenum Press, New York, 1997).
66. Accad, M. et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1. J. Clin. Invest. 105, 711-719 (2000).
67. Haley, R.W. & Dietschy, J.M. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch. Neurol. 57, 1410-1412 (2000).
68. Salen, G. & Grundy, S.M. The metabolism of cholestanol, cholesterol and bile acids in cerebrotendinous xanthomatosis. J. Clin. Invest. 52, 2822-2835 (1973).
69. Salen, G. et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N. Engl. J. Med. 316, 1233-1238 (1987).
70. Bjorkem, I. & Boberg, K.M. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. in The Metabolic and Molecular Bases of Inherited Disease (eds. Scriver, C.R., Beaudet, A.L., Sly, W.S. & Valle, D.) 2073-2099 (McGraw-Hill, New York, 1995).